Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IMRX

Immuneering (IMRX)

Immuneering Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IMRX
DateTimeSourceHeadlineSymbolCompany
05/29/20244:05PMGlobeNewswire Inc.Immuneering to Present at the Jefferies Global Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
05/23/20244:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
05/23/20244:18PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
05/23/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
05/23/20244:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
05/23/20244:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
05/07/20244:05PMGlobeNewswire Inc.Immuneering Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
05/07/20244:04PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
05/06/20244:30PMGlobeNewswire Inc.Immuneering Recognizes Melanoma Awareness MonthNASDAQ:IMRXImmuneering Corporation
04/09/202412:00PMGlobeNewswire Inc.IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsNASDAQ:IMRXImmuneering Corporation
04/03/20244:05PMGlobeNewswire Inc.Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
03/27/20248:00AMGlobeNewswire Inc.Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS MutationsNASDAQ:IMRXImmuneering Corporation
03/14/20247:00AMGlobeNewswire Inc.Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid TumorsNASDAQ:IMRXImmuneering Corporation
03/12/20248:00AMGlobeNewswire Inc.Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of DirectorsNASDAQ:IMRXImmuneering Corporation
03/11/20248:00AMGlobeNewswire Inc.Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid TumorsNASDAQ:IMRXImmuneering Corporation
03/05/20245:00PMGlobeNewswire Inc.Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024NASDAQ:IMRXImmuneering Corporation
03/04/20248:00AMGlobeNewswire Inc.Immuneering to Participate in the Cowen 44th Annual Health Care ConferenceNASDAQ:IMRXImmuneering Corporation
03/01/20248:05AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IMRXImmuneering Corporation
03/01/20248:00AMGlobeNewswire Inc.Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
03/01/20247:58AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
02/20/20248:00AMGlobeNewswire Inc.Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic CancerNASDAQ:IMRXImmuneering Corporation
02/09/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
02/09/20244:26PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
02/09/20244:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
02/09/20244:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
02/09/20244:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
02/09/20244:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
02/02/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
01/16/20244:37PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMRXImmuneering Corporation
01/02/20244:26PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
 Showing the most relevant articles for your search:NASDAQ:IMRX

Your Recent History

Delayed Upgrade Clock